Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine. Karron RA, Key NS, Sharfstein JM. JAMA 2021 Apr 30. pii: 2779732. doi: 10.1001/jama.2021.7637.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Karron RA, Key NS, Sharfstein JM. Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine. JAMA 2021 Apr 30. pii: 2779732. doi: 10.1001/jama.2021.7637.
PMID: 33929484